Biologics Contract Manufacturing Market Size USD 83.47 Billion by 2033, CAGR 14.0%, North America Leads the Market | Key Players Lonza, Samsung Biologics, Wuxi Biologics

The global Biologics Contract Manufacturing Market reached US$ 26.03 billion in 2024 and is expected to reach US$ 83.47 billion by 2033, growing at a CAGR of 14.0% during the forecast period 2025-2033. Market growth is driven by rising demand for biologic drugs, increasing research and development investments by biopharmaceutical and biotech companies, and strategic collaborations with contract manufacturing organizations (CMOs) to scale production efficiently and reduce time-to-market.

North America continues to dominate the biologics contract manufacturing market due to the presence of leading CMOs and strong collaborations with biopharma and biotech companies. Meanwhile, the Asia-Pacific region is expected to witness the highest growth rate, fueled by increasing investments in biologics development, favorable regulatory initiatives, and expanding access to biologic therapies for patients with high unmet medical needs. Strategic partnerships, technological advancements in manufacturing processes, and the growing pipeline of biologic drugs are further strengthening the long-term growth outlook of the global biologics contract manufacturing market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/biologics-contract-manufacturing-market?sai-v

The Biologics Contract Manufacturing Market refers to the global industry providing outsourced production and development services for biologic drugs, including vaccines, antibodies, and recombinant proteins, on behalf of pharmaceutical and biotech companies.

Key Developments
✅ January 2026: In North America, contract manufacturers expanded single‐use bioreactor and flexible facility capacity to support increased biologics production for oncology and immunology therapeutic pipelines.

✅ December 2025: In Europe, demand grew for fill‐finish and aseptic processing services as biotech firms advanced complex biologics, including antibody‐drug conjugates and fusion proteins, toward commercialization.

✅ November 2025: In Asia‐Pacific, companies scaled up CHO cell line development and process optimization capabilities to attract early‐stage biologics clients and enhance regional manufacturing competitiveness.

✅ October 2025: In Latin America, contract manufacturing organizations enhanced quality systems and regulatory compliance support to meet international biologics production standards.

✅ September 2025: In the Middle East, investment increased in cold chain and bioprocess logistics infrastructure to support growing biologics contract manufacturing demand.

✅ August 2025: In Africa, pilot biologics fill‐finish facilities were initiated to broaden local production capacity and reduce dependency on imports for essential biologic therapies.

Mergers & Acquisitions
✅ January 2026: In North America, a leading biologics CMO acquired a cell culture media and process development specialist to enhance upstream capabilities for complex biologic programs.

✅ December 2025: In Europe, a global biologics contract manufacturing services provider acquired a regional aseptic fill‐finish facility to expand its capacity and geographic reach.

✅ November 2025: In Asia‐Pacific, a regional healthcare technology group acquired a biologics analytics and quality control lab to strengthen its end‐to‐end contract manufacturing offerings.

Key Players
Wuxi Biologics | AGC Biologics | Lonza | FUJIFILM Diosynth Biotechnologies | Thermo Fisher Scientific Inc. | KBI Biopharma | Vetter Pharma | Recipharm AB | Abzena Ltd | Samsung Biologics | Eurofins CDMO | Catalent | Boehringer Ingelheim International GmbH

Key Highlights
Lonza holds 18.9% share, driven by its global biomanufacturing footprint, extensive biologics development expertise, and strong partnerships with leading biotech and pharmaceutical companies.

Samsung Biologics holds 16.3% share, supported by large-scale commercial production capabilities, flexible contract manufacturing services, and strong adoption by multinational biologics developers.

Wuxi Biologics holds 14.7% share, benefiting from end-to-end biologics development and manufacturing services, rapid capacity expansion, and strong presence in Asia-Pacific markets.

Thermo Fisher Scientific Inc. holds 12.5% share, driven by integrated CDMO services, advanced process technologies, and broad global reach across biologics development and production.

FUJIFILM Diosynth Biotechnologies holds 8.9% share, supported by flexible manufacturing platforms, bioprocess innovation, and strong collaborations with biotech innovators.

AGC Biologics holds 7.4% share, benefiting from diverse biologics services, including viral vectors and monoclonal antibodies, with a focus on quality and regulatory compliance.

Catalent holds 6.2% share, driven by contract development and manufacturing services, advanced delivery technologies, and global client partnerships.

Vetter Pharma holds 5.1% share, supported by expertise in aseptic filling and packaging of biologics, with strong demand from commercial clients.

Boehringer Ingelheim International GmbH holds 3.6% share, leveraging its biologics development and manufacturing capabilities for both internal pipelines and external CDMO services.

Recipharm AB holds 2.8% share, benefiting from flexible manufacturing solutions and expansion into biologics contract services.

Abzena Ltd holds 2.1% share, driven by early-stage development and process optimization services for monoclonal antibodies and other biologics.

Eurofins CDMO holds 1.5% share, supported by integrated development, analytics, and manufacturing solutions catering to small and mid-sized biotech companies.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=biologics-contract-manufacturing-market?sai-v

Market Drivers
- Rising demand for biologics therapies such as monoclonal antibodies, vaccines, and gene therapies.

- Growing trend of outsourcing biologics manufacturing to reduce cost, time-to-market, and regulatory burden.

- Increasing investment in R&D and clinical trials by pharmaceutical and biotechnology companies.

- Advancements in bioprocessing technologies, cell culture systems, and quality control methods.

- Expansion of biologics production capacities in emerging and established markets.

Industry Developments
- Continuous innovation in upstream and downstream biologics manufacturing processes.

- Strategic partnerships and long-term agreements between biotech firms and contract manufacturing organizations (CMOs).

- Expansion of global manufacturing facilities to meet increasing biologics demand.

- Adoption of advanced automation, single-use systems, and flexible manufacturing platforms.

- Growing focus on regulatory compliance, quality assurance, and process optimization for biologics production.

Regional Insights
North America - 40% share: "Driven by strong pharmaceutical and biotechnology presence, high outsourcing adoption, advanced manufacturing infrastructure, and regulatory expertise."

Europe - 28% share: "Supported by established biologics industry, increasing CMO partnerships, and adoption of innovative manufacturing technologies."

Asia Pacific - 27% share: "Fueled by rapid growth of biotech firms, cost-effective manufacturing facilities, government support, and increasing contract manufacturing demand."

Latin America - 3% share: "Driven by expanding biologics research initiatives and increasing outsourcing partnerships."

Middle East & Africa - 2% share: "Supported by emerging biologics production capabilities, growing healthcare investment, and expanding biotech industry presence."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biologics-contract-manufacturing-market?sai-v

Key Segments

By Product Type
Monoclonal antibodies dominate the market, driven by their widespread use in oncology, autoimmune diseases, and other therapeutic areas. Recombinant proteins hold a significant share, supported by increasing adoption in therapeutics, vaccines, and diagnostic applications. Other biologics, including vaccines, cell therapies, and nucleic acid-based products, are witnessing steady growth due to expanding R&D pipelines and personalized medicine initiatives.

By Platform
Mammalian cell culture platforms dominate the market, driven by their ability to produce complex proteins with human-like post-translational modifications. Microbial platforms hold a substantial share, supported by cost-effectiveness and high-yield production for simpler biologics. Other platforms, including insect and plant-based systems, are growing steadily, supported by innovations in biomanufacturing and scalability.

By Application
Therapeutics represent the largest application segment, driven by increasing biologics demand for chronic and life-threatening diseases. Vaccine production holds a significant share, supported by ongoing immunization programs and rapid vaccine development needs. Diagnostics applications are gaining traction due to biologics-based assays and reagents. Other applications include research, clinical trials, and industrial bioprocessing.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.